KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $29.3 million.

  • Bionano Genomics' Total Liabilities fell 2398.04% to $29.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.3 million, marking a year-over-year decrease of 2398.04%. This contributed to the annual value of $41.3 million for FY2024, which is 6507.73% down from last year.
  • According to the latest figures from Q3 2025, Bionano Genomics' Total Liabilities is $29.3 million, which was down 2398.04% from $30.6 million recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Total Liabilities ranged from a high of $118.2 million in Q4 2023 and a low of $10.9 million during Q2 2021
  • For the 5-year period, Bionano Genomics' Total Liabilities averaged around $45.1 million, with its median value being $40.0 million (2021).
  • As far as peak fluctuations go, Bionano Genomics' Total Liabilities skyrocketed by 23645.25% in 2022, and later tumbled by 6507.73% in 2024.
  • Over the past 5 years, Bionano Genomics' Total Liabilities (Quarter) stood at $40.0 million in 2021, then skyrocketed by 45.33% to $58.1 million in 2022, then surged by 103.51% to $118.2 million in 2023, then crashed by 65.08% to $41.3 million in 2024, then fell by 29.14% to $29.3 million in 2025.
  • Its last three reported values are $29.3 million in Q3 2025, $30.6 million for Q2 2025, and $30.2 million during Q1 2025.